Evaluation of therapeutic effects of 125I particles brachytherapy for recurrent bladder cancer

Abstract

The aim of the present study was to evaluate the clinical value of 125I particles implantation in the treatment of recurrent bladder cancer. The study is a retrospective analysis of 32 patients with recurrent bladder cancer treated between May 2010 and January 2010. Of these, 16 cases (chemotherapy group) received conventional chemotherapy. A total of 16 patients (125I group) received radiotherapy with 125I particles, followed by conventional chemotherapy. By guidance of B ultrasound, 125I radioactive particles were implanted. All 32 patients were relieved after treatment, and the tumors were significantly reduced after 2 months. However, the tumors in the 125I group were significantly smaller than those in the chemotherapy group (P<0.05). The patients were followed-up for 1 year and no recurrence was found. Additionally, no complications occurred. Compared with the chemotherapy group, the tumor volume of the 125I group was significantly reduced (P<0.05). The disease-free survival and 5-year survival rates of the patients in the follow-up showed that the disease-free survival and 5-year survival rates of the patients in 125I group were significantly improved compared to those in the chemotherapy group. Therefore, the results have shown that 125I radioactive particles in the treatment of bladder cancer improve the symptoms of patients with bladder cancer in the short term, and continuously kill residual tumor and prevent recurrence.

The efficacy of the combination of percutaneous transhepatic biliary drainage and 125I stranded seeds for malignant bile duct obstruction treatment

“…In group A, continuous low energy intracavitary brachytherapy can inhibit tumor mitosis, causing the tumor cells to remain in the G2 phase, resulting in eventual tumor cell killing by radiation. This approach can prevent tumor growth into the lumen of internal-external drainage tube, thereby reducing the risk of internal-external drainage tube stenosis or occlusion, as compared to the drainage alone [31,32]. Due to the long biliary obstruction-free time, this approach also reduces the frequency, at which patients undergo an exchange of internal-external drainage tubes and hospital stay, in addition to the cost of treatment.…”

Iodine-125 seed implantation combined with arterial chemoembolization therapy for pain palliation in metastatic bone cancer: a retrospective study

“…7 Meanwhile, 125 I radioactive particles are accurately implanted into the tumor target area and continuously emit radiation, which can significantly increase the dose of tumor receiving and achieve the three dimensional conformal treatment in the target area. 8,9 The combination therapy not only can achieve the goal of tumor ischemic necrosis, but also can relieve pain and improve patients' quality of life. However, there have been very few studies that evaluate the efficacy and safety of the combination therapy.…”

Overall survival, disease‐specific survival and local recurrence outcomes in patients with muscle‐invasive bladder cancer treated with external beam radiotherapy and brachytherapy: a systematic review

“…All patients received EBRT before BT except for two studies. In one of these studies patients received BT as a monotherapy with or without adjuvant chemotherapy [20]; and in the other, BT was delivered as a monotherapy, with EBRT or RC being offered if unsuccessful [21]. BT was delivered via a range of techniques.…”

“…The LR rate ranged from 0% to 32%. Of note the study that reported a 0% LR rate was small ( n = 16) and included only patients with recurrent tumours [20].…”

“…Acute and late AEs were recorded across most studies except by Zhou et al [20], who reported no complications after BT. The most commonly used reporting system was the Radiation Therapy Oncology Group (RTOG), used by seven studies followed by the Common Terminology Criteria for Adverse Events (CTCAE), used by five.…”